SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?

Key Takeaways Solventum (SOLV) posted a strong Q1 FY25 with 4.3% organic growth and raised full-year revenue guidance. SOLV's growth is driven by improved commercial focus and product innovation in MedSurg, Dental, and HIS. Tariff risks loom, but SOLV's strategic mitigations to support sustained profitability.Solventum Corporation (SOLV) delivered a robust first-quarter performance, reflecting the company’s progress on its multi-phase transformation and renewed commercial focus. The company reported earni ...